Business Wire

CA-VELODYNE-LIDAR,-INC.

15.11.2018 14:02:11 CET | Business Wire | Press release

Share
Automotive Innovator, Rick Tewell, Promoted to Chief Operating Officer at Velodyne Lidar

Velodyne Lidar, Inc. announces the promotion of Rick Tewell to Chief Operating Officer. Tewell assumes leadership of the company’s vast manufacturing efforts at its Megafactory in San Jose, California. He joined the company in September 2017 as Senior Vice President of Automated Manufacturing and was promoted to Chief Advanced Manufacturing Officer prior to the promotion to COO. He brings a wealth of expertise to the day-to-day production of Velodyne’s industry-leading lidar sensor product line.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005168/en/

According to Marta Hall, Velodyne’s President and Chief Business Development Officer, Velodyne “recruited Rick Tewell to manage Robotics and Advanced Technology, and within a year it was clear he could lead Operations as COO. Velodyne Lidar is at the extreme edge of high tech, and Rick meets the challenge with da Vinci-like multiple talents. In the last three months Rick upgraded the entire Velodyne Megafactory with robotics and newly designed innovative processes for production. As COO he brings a futuristic vision and fresh energy to the operations of the company.”

“My main responsibility,” said Tewell, “is to take a design that came from the mind of a genius, David Hall [Velodyne’s Founder and CEO], and make it into a product worthy of the Velodyne name. I work with David and Anand [Gopalan, Velodyne’s Chief Technology Officer] to translate these wonderful designs that have the ability to change the world into something that is manufacturable and then ramp production to meet the demand. To take an invention from Dave Hall and turn it into a manufacturable product is a huge responsibility and one that I take very seriously. It’s an incredible opportunity. I get out of bed excited to go to work, and I go to bed thinking about it.”

According to Tewell, the job of Chief Operating Officer at Velodyne is unlike any other. Between designing and manufacturing the highest quality sensors on the market comes the equally challenging task of inventing and building the machines that then build the sensors.

“For our sensors to be able to see so far and produce incredibly accurate data for autonomous vehicles to use, we have to employ incredibly precise processes, which include utilizing robotics and automation. So we need to also invent the machines that will build our sensors.” Given the uniqueness of Velodyne’s products, Tewell pointed out that he must address the complex processes of “taking something that’s never been invented or built before and building tens of thousands -- hundreds of thousands -- millions of them. It is a whole series of inventions to produce the sensor invention. So, it is not just the genius of the lidar itself; it’s the genius of saying, ‘This is what you are going to need to invent in order to manufacture the sensor.’”

Before coming to Velodyne, Tewell established a successful career in the automotive semiconductor industry, including stops at Fujitsu and NVIDIA. Rick remembers, “The idea that cars eventually would be robots emerged while Dave Hall was participating in the DARPA Grand Challenge. At NVIDIA we were creating the brains that would be used in self-driving cars.” Tewell’s interest and experience in developing key technologies for autonomous mobility grew over the years. Finally, Tewell decided to join Velodyne with the clear realization that he would be “aligning with a company that will be one of, if not the, principal company in the self-driving industry.”

Tewell recognizes the essential role Velodyne’s products have in enabling safe mobility at scale. “We are working hard to meet the next wave of demand for sensors to put on autonomous vehicles. Scaling up will drive the cost down to where the price is attractive to all customers. But we will never compromise on quality. It is critical from an operations standpoint that our product will ultimately impact someone’s life. This realization needs to permeate every aspect of what we do. This is not a piece of technology that is going to stay in a box. When you put a sensor on a car the person in that car is trusting that technology to keep them safe.”

About Velodyne Lidar

Founded in 1983 and headquartered in Silicon Valley, Velodyne is a technology company known worldwide for its real-time 3D lidar computing and software platforms. The company evolved after founder David Hall invented the HDL-64 Solid-State Hybrid lidar sensor in 2005. Since then, Velodyne Lidar, Inc. emerged as the unmatched market leader of real-time 3D vision systems used in a variety of commercial applications including autonomous vehicles, vehicle safety systems, mobile mapping, aerial mapping, and security. Its products range from the high-performance, surround view Ultra-Puck™ VLP-32, classic HDL-32/64 and cost-effective VLP-16, the new VLS-128, to the upcoming, hidden Velarray™. Velodyne’s rich suite of perception software and algorithms are the key enablers of its perception systems. Velodyne supports customers from offices in San Jose, Detroit, Frankfurt, and Beijing. For more information, visit http://www.velodynelidar.com .

Contact:

David Cumpston Landis Communications for Velodyne Lidar, Inc. (415) 359-2316 velodyne@landispr.com

Social Media:

https://www.facebook.com/velodyneLiDAR/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye